Drug intelligence / Profile preview

AL5927

Development stage: Unknown
Lead developer: Alcon
Modality: Small Molecules
Administration: Ophthalmic

Overview

AL5927 is an experimental small molecule sulfonamide that acts as a potent inhibitor of carbonic anhydrase 2 (CA2). Developed by Alcon Laboratories, the compound belongs to a chemical class frequently investigated for the treatment of glaucoma and ocular hypertension due to its ability to reduce aqueous humor production. Structurally, AL5927 is characterized by the formula C12H14N2O5S3 and has been extensively utilized in biochemical research and X-ray crystallography to study the binding dynamics and structural biology of the carbonic anhydrase enzyme family. Despite its utility as a research tool, AL5927 has not progressed into clinical trials and is not currently associated with any approved therapeutic indications.

Other names: AL-5927AL5927AL 5927

Targets

CA2 (Carbonic Anhydrase 2)

Beyond the preview

Go deeper on AL5927.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AL5927.

Explore the full profile